Towards Effective and Safe Thrombolysis and Thromboprophylaxis: Preclinical Testing of a Novel Antibody-Targeted Recombinant Plasminogen Activator Directed Against Activated Platelets.

CONCLUSIONS: Targeting of scuPA to activated GPIIb/IIIa allows effective thrombolysis and the potential novel use as a fibrinolytic agent for thromboprophylaxis without bleeding complications. PMID: 24508759 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24508759?dopt=Abstract

Source: Circulation Research - February 9, 2014 Category: Cardiology Authors: Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, Alt K, Huang D, Jia F, Ahrens I, Medcalf RL, Peter K, Hagemeyer CE Tags: Circ Res Source Type: research